How many investments has Novo Holdings made?

Novo Holdings has 120 tracked investments, 19 of which have exited, including 22 dated in the last 24 months.

What stage does Novo Holdings invest at?

Novo Holdings invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.

What is Novo Holdings's typical check size?

Novo Holdings typically writes checks of $1.1M – $54M.

What sectors does Novo Holdings focus on?

Novo Holdings focuses on AgTech, Biotech, Cleantech, Climate Tech, Digital Health, Healthtech, Impact & Social Good, Longevity, Medical Devices, New Materials.

Where is Novo Holdings located?

Novo Holdings is headquartered in Copenhagen, DK.

Does Novo Holdings lead rounds?

Novo Holdings has led 18 of the 49 rounds where its role is on record.

Who does Novo Holdings co-invest with?

Novo Holdings most often shares deals with Jeito Capital, Industrifonden, OrbiMed, among 47 tracked co-investors.

Novo Holdings

Family office

Copenhagen · Pre-Seed–Late Stage · 47 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Novo Holdings

1,860 people in our graph share verified history with the Novo Holdings team — schools, employers, funds. One of them is your warm intro.

Wesley Chanunlockedknows Aleks Engel · together at Massachusetts Institute of Technology (overlapped)

knows the team · via MIT Sloan School of Management

knows the team · via McKinsey & Company

×4knows the team · via Cornell

×2knows the team · via Massachusetts Institute of Technology

×3knows the team · via Loughborough University

✨ Fox Verdict

Investment thesis

Novo Holdings invests to improve human health and the sustainability of society and the planet while generating attractive long-term returns for the Novo Nordisk Foundation. It focuses on life sciences and bio-sustainability, backing companies at all stages of development, from early-stage ventures through growth and public equities. Alongside significant direct investments, it maintains a broadly diversified capital investment allocation spanning equities, bonds, real estate, infrastructure and private equity. The firm positions itself as a responsible, values-driven investor aiming to deliver both strong financial returns and positive societal impact, operating with a long-term return perspective across global markets.

Source: firm website, verified Aug 3, 2026.

Stage

Pre-Seed–Late Stage

Check

$1.1M – $54M

Copenhagen, DK

Instruments

Equity

Founded

1999

Last 12 months

9 investments

AUM

$108B

Tracked investments

120

Unicorns

IPOs

Acquisitions

Team · 47 people

from the firm's website & curated & public directories

Aaron Nelson· Partner· United Statesin

Aaron Nelson is a Partner in Novo Holdings' US Venture Investments unit, which he joined in June 2025. He was previously Managing Director at the Novartis Venture Fund, where he led Seed and Series A investments in therapeutic drug discovery, and contributed to Novartis's digital health investment program dRx Capital. Earlier he worked across Novartis Research & Development units including Trials of the Future and Investigative Toxicology. He holds a BA from Cornell University, a PhD in Cell and Microbiology from the University of Pennsylvania, and an MD from Tufts University, and conducted post-doctoral studies at the Karolinska Institutet.

a•••@novartis.comreveal

Abhijeet Lele· Senior Partner· United States

Abhijeet Lele is Senior Partner and Head of US Principal Investments at Novo Holdings, which he joined in September 2020, with over 20 years of healthcare investment experience. He previously led US healthcare investing at Temasek and, before that, at Investor AB/Patricia Industries, and began his investing career at EGS Partners, a healthcare-focused hedge fund. Earlier in his career he was an Engagement Manager at McKinsey & Company and held operating roles in the pharmaceutical industry. He holds an MA in Natural Sciences from Cambridge University and an MBA from Cornell University.

Aleks Engel· Partner· Bostonin

Aleks Engel is a Partner in Novo Holdings' Planetary Health Investments team, based in Boston, having joined the firm in 2014 and previously worked on its Principal Investments and Seed Investments teams in Copenhagen. Before Novo Holdings, he held roles at Baxter International, Pfizer Global Research and Development, Thomson Scientific & Healthcare, and McKinsey & Company. He holds a PhD in Biochemical Engineering and an MSc in Chemical Engineering Practice from MIT.

Amer Sheikh· Partner· Copenhagen, Capital Region of Denmark, Denmarkin

Amer Sheikh joined Novo Holdings Seed Investments as a Partner in January 2026, where he leads the firm's Quantum Technologies investment strategy, covering quantum computing and sensing, advanced computing, and enabling software and infrastructure. He previously worked as an Investment Director at HSBC Ventures leading its Quantum and Deep Tech themes, and held senior investment roles at Sky Ventures and Centrica Ventures. He holds a PhD in Physics from Loughborough University and the Institut Laue Langevin and a BSc (Hons) in Physics.

Amit Kakar· Managing Partner· Singaporein

Amit Kakar joined Novo Holdings Asia in August 2020 as Head of Asia, leading investments and partnerships across China, Japan, Singapore, and Southeast Asia. He has over 25 years of healthcare experience, previously holding roles at Everlife Asia (Head of M&A and Business Development), the Avenue Capital Group (Head of healthcare investments for Asia), and GE Healthcare. He holds a medical degree with a postgraduate qualification in Radiation and Nuclear Medicine from Tata Memorial Hospital and Cancer Centre in Mumbai, India.

Anders Bendsen Spohr· Managing Partner, Head of Planetary Health Investments

Anders Bendsen Spohr joined Novo Holdings A/S in 2017 and serves as Managing Partner and Head of the Planetary Health Investments team. Before Novo Holdings, he held supply chain and operations leadership roles including VP of Global Product Supply at Xellia Pharmaceuticals, EVP of Global Product Supply at Leo Pharma, and VP of Global Supply Chain at Novozymes. He holds a PhD in Biotechnology and an MSc in Chemical Engineering from the Technical University of Denmark, along with a graduate diploma in Business Administration from Copenhagen Business School.

Andreas Nickelsen· Partner

Andreas Nickelsen is a Partner in Novo Capital Investors at Novo Holdings, having joined in March 2022. He holds an MSc in Economics from the University of Copenhagen and became a CFA Charterholder in 2011. Before Novo Holdings, he worked at Realdania, Sampension, and Ørsted.

Anna Fan· Senior Partner, Public Equity· San Francisco, California

Anna Fan is a Senior Partner at Novo Holdings, where she leads the public investing strategy for the Venture Investments team and serves on the Life Sciences Operating Committee. Before joining the firm, she covered publicly traded biotech companies at Sectoral Asset Management and began her career in financial advisory serving fund managers and corporate clients in life sciences. She holds a Ph.D. and B.Sc. in Biochemistry from McGill University and is a CFA charterholder.

Christoffer Søderberg· Managing Partner

Managing Partner in Principal Investments and a member of the Executive and Life Science Leadership Teams.

Morten Beck Jørgensen· Managing Partner

Managing Partner in Capital Investments and a member of the Executive and Capital Investments Leadership Teams.

m•••@novo.dkreveal

Camilla Petrycer Hansen· Partner· Copenhagen, Capital Region of Denmark, Denmarkin

Camilla Petrycer Hansen is a Partner at Novo Holdings, where she works with the REPAIR Impact Fund. She focuses on early-stage life science investments.

c•••@novo.dkreveal

Emmanuelle Coutanceau· Partner· Copenhagen, Capital Region of Denmark, Denmarkin

Emmanuelle Coutanceau is a Partner in Seed Investments at Novo Holdings, focused on early-stage biotech investment and company creation. She has over 15 years of experience backing innovations from the laboratory to the clinic and has served as a board director on strategic, compensation, and governance committees.

e•••@novo.dkreveal

Eric M. Snyder· Partner· Greater Bostonin

e•••@novo.dkreveal

Helen Gaffney· Partner· Copenhagen, Capital Region of Denmark, Denmarkin

h•••@novo.dkreveal

Henrik Kjær Hansen· Senior Partner

h•••@novo.dkreveal

Jeroen Bakker· Partner· Copenhagen, Capital Region of Denmark, Denmarkin

j•••@novo.dkreveal

Jørgen Søberg Petersen· Senior Partner· Utrecht, Utrecht, Netherlandsin

Jørgen Søberg Petersen is a Senior Partner at Novo Holdings, where he has worked since 2017 on the venture capital team focused on building and scaling biotech companies. Trained as a physician-scientist in Denmark and the United States, he previously held R&D and leadership roles at Merck and Novo Nordisk and co-founded Zealand Pharma (NASDAQ: ZEAL.CO), where he served as Chief Scientific Officer. He has been a founding executive or investor in more than a dozen biotech companies, several of which have been taken public or sold.

j•••@novo.dkreveal

Scott A. Beardsley· Managing Partner

s•••@novo.dkreveal

Søren Møller· Managing Partner· Copenhagen, Capital Region of Denmark, Denmarkin

s•••@novo.dkreveal

Jim Trenkle· Partner, Venture Investments· Cambridge, Massachusettsin 𝕏

Max Klement· Partner, Venture Investments· Amsterdam, Netherlandsin

Max Klement is a Partner in Venture Investments at Novo Holdings. He has an engineering background and experience in the global biotech industry, focusing on the development and translation of biomedical science toward human health applications.

Heath Lukatch· Partner· San Francisco, Californiain

Hongjie Hu· Partner· New York, New Yorkin

Hongjie Hu is a Partner in Growth Investments at Novo Holdings, where he focuses on investments at the intersection of healthcare, life sciences, and technology across North America, Europe, Israel, and Asia.

Alan Liu· Principal

Alan Liu is a Principal in the Planetary Health Investments department at Novo Holdings A/S, which he joined in 2020, where he works on deal sourcing, execution, and portfolio management. Before Novo Holdings, he worked in J.P. Morgan's European Healthcare team in London and its North Asia M&A team in Hong Kong, handling private and public transactions across multiple industries. He holds a BSc in Quantitative Finance from CUHK, an MPhil in Biotechnology from Cambridge, and an MSc in Integrated Immunology from Oxford.

Anders Lykke Iversen· Principal, Principal Investments· Copenhagen, Capital Region of Denmark, Denmarkin

Anders Lykke Iversen joined Novo Holdings in November 2017 as an Associate in Principal Investments and works on deal sourcing, execution, and portfolio management. Before Novo Holdings, he was a management consultant at Bain & Company in Copenhagen, focusing on due diligence and post-acquisition work for private equity clients and strategy, performance improvement, and M&A for Nordic corporates. He holds a BSc in International Business and an MSc in Finance & Strategic Management from Copenhagen Business School.

a•••@novo.dkreveal

Angela Jong· Principal· San Francisco Bay Areain

Angela Jong joined Novo Holdings in 2025 as a Principal on the Planetary Health Investments team. She was previously a Vice President at Advent International working on healthcare buyout investments, and earlier worked at Stellar Health, a healthcare technology startup, and at TA Associates on healthcare growth and buyout investments. She started her career in investment banking at Morgan Stanley.

Gábor Gyülvészi· Principal

g•••@novo.dkreveal

Daniel Rasmussen· Principal· Copenhagen, Denmarkin

Daniel Rasmussen is a Principal at Novo Holdings, the investment company managing assets for the Novo Nordisk Foundation. He leads fund-of-funds and co-investment activities in biotechnology, quantum technology, and planetary health, and brings experience from roles at BASF Venture Capital, Verdane, and Oaklins across venture capital, growth equity, and corporate finance.

Raymond Camahort· Principal· Boston, Massachusetts

Alex Grooten· Senior Manager, Head of Accounting· Copenhagen, Capital Region of Denmark, Denmarkin

Alex Grooten works at Novo Holdings in the Finance & Operations department, serving as Senior Manager, Head of Accounting.

Álvaro Gallego Jurado· Manager (Rewards Manager)

Álvaro Gallego Jurado joined Novo Holdings' People & Organisation department as a Rewards Manager in 2024, focusing on the governance of reward frameworks. He previously worked as a Performance & Rewards Partner Manager at Pandora A/S and gained earlier rewards experience at tech and security companies. A Spanish national, he holds an MChem in Chemistry and Materials Chemistry from the University of Edinburgh.

Amalie Stokkeland· Senior Associate· Los Angeles Metropolitan Area

Amalie Stokkeland joined Novo Holdings A/S in February 2025 as a Senior Associate on the Planetary Health Investments team, where she works on deal sourcing, execution, and portfolio management. She previously worked in investment banking at ABG Sundal Collier on M&A and ECM transactions. She holds an MSc in Finance and a BSc in Economics and Business Administration from Aarhus University BSS.

Amy Kacprowicz· Senior Specialist· Bostonin

Amy Kacprowicz works at Novo Holdings US Inc. within the Strategy and People department. She joined Novo Ventures (US), Inc. as an Office Manager in Boston, then moved to the People & Organization team as an HR coordinator supporting HR operations in the Boston and San Francisco offices in 2023. She holds a Bachelor of Arts from Hobart and William Smith Colleges and a graduate certificate in Human Resources from Northeastern University, following earlier roles in healthcare administration.

Andeta Jonuzaj· Senior Specialist

Andeta Jonuzaj joined Novo Holdings in 2021 as a compliance specialist, dividing her time between the Finance and Ventures teams. She previously spent 12 years in the banking sector, handling financial closing controls, compliance tasks including Know Your Client, and reporting of various statements. She holds a Master's degree in Financial Management.

Anette Vium Sørensen· Tax Manager

Tax Manager within Finance & Operations.

Anne Dorte Stensberg Jensen· Executive Assistant, Principal Investments

Anne Dorte Stensberg Jensen joined Novo Holdings A/S as an Executive Assistant in the Principal Investments department in April 2024. She previously worked as a personal assistant at Copenhagen Infrastructure Partners and held PA and customer service roles at WS Audiology A/S. She holds a BA in German Business Communication from the University of Southern Denmark.

Barbara Fiorini· General Counsel, Executive Director

Barbara Fiorini is General Counsel at Novo Holdings A/S, which she joined in 2020, and has been part of the Executive Leadership Team since 2021, leading the legal department and handling the company's legal affairs across investments, divestments, and portfolio matters. She previously handled legal and compliance work for the Europe region at ISS World Services A/S and served as senior legal counsel at Genmab, including a period at Genmab US in New Jersey, and earlier worked as an M&A attorney at the law firm Plesner in Copenhagen. She holds a Master in Law from the University of Copenhagen and is a member of the Danish Bar Association.

Helle Bach· Chief People Officer· Copenhagen, Capital Region of Denmark, Denmarkin

Helle Bach joined Novo Holdings in 2025 as Chief People Officer, sitting within the Strategy & People organisation and on the Executive Leadership Team, and oversees the People & Organisation function across offices in Denmark, the US, London and APAC. She previously led the global HR function at DSV A/S, where she built the Group HR function and took part in company M&A, and earlier led the people area at Egmont International Holding after starting her career as a management consultant at Rambøll Management. She holds a Master of Political Science from Aarhus University (2001).

Kasim Kutay· CEO· UKin

Kasim Kutay has served as Chief Executive Officer of Novo Holdings A/S since September 2016 and sits on the Boards of Directors of Novo Nordisk A/S and Novonesis A/S. He was previously a Partner and member of the Global Management Committee at Moelis & Co. (2009–2016) and held various roles at Morgan Stanley from 1989 to 2007, including chair of the European Healthcare Group. He holds an MSc and BSc in Economics from the London School of Economics (LSE).

k•••@novo.dkreveal

Kasper Sobfeldt Jahn· Chief Strategy Officer· Houston, Texas, United Statesin

Kasper Jahn joined Novo Holdings in 2014 with the Principal Investments team, which handles healthcare buyout investments. He moved to lead the Strategy Office in 2021 and joined the Executive Leadership Team in 2025, taking on responsibility for People & Organisation. Before Novo Holdings, he was an Engagement Manager at McKinsey & Company in Copenhagen serving pharmaceutical and medical device companies, and he holds an MSc and PhD in Nanoscience from Aarhus University and is a CFA Charterholder.

Nigel Govett· CFO· Copenhagen, Capital Region of Denmark, Denmarkin

Nigel Govett has served as Chief Financial Officer of Novo Holdings A/S since March 2022, and sits on the Board of Directors of NNIT A/S as Chair of its Audit Committee. He previously held CFO roles at Oman Infrastructure Investment Management and the Sovereign Wealth Fund of Oman, and director positions at EQT and Close Brothers. A UK national, he is a Fellow of the ACCA and holds a BA (Hons) in Historical Studies from the University of Sunderland.

Avra van der Zee· Advisory Group Member· New York, New York, United Statesin

Avra van der Zee is a General Partner at SOSV, where she helps lead HAX's global climate investing strategy. She previously spent five years as COO of Elemental Impact, overseeing investments, communications, and operations, and earlier served as COO and General Counsel of JUMP (an SOSV investment) through its acquisition by Uber. She currently holds several board and advisory positions and focuses on helping founders scale hardware and climate technologies.

Kuang He· Vice President· Paris, Francein

Kuang He is a biotech venture capitalist and board observer at Booster Therapeutics.

Peter Eckes· Advisory Group Planetary Health· Europein

Peter Eckes is an operational partner at Astanor, which he joined in May 2023, where he works with the investment team and supports portfolio companies. He spent 32 years at BASF SE, including roles as CTO of its Agricultural Solutions R&D and Regulatory team and membership of the company's global Technology Leadership Team, with experience across agriculture, nutrition, specialty chemicals, and industrial biotechnology. His background covers R&D strategy, technology portfolio management, and large organizational transformations.

Thomas Vanderstichele· Associate· Londonin 𝕏

Heather Ludvigsen· Copenhagen, Denmarkin

Heather Ludvigsen is Senior Manager of Venture Investments at Novo Holdings A/S. She holds a CPA credential and has worked in corporate audit, internal audit, and financial reporting across external and internal functions. Her experience encompasses investment fund accounting, regulatory compliance, budgeting, and process controls review.

Kenneth Harrison· San Francisco, California

What they invest in

from 111 of 120 portfolio companies

Biotech ×91Healthtech ×58Medical Devices ×43Deep Tech ×19Digital Health ×17AI & Machine Learning ×14New Materials ×10Advanced Manufacturing ×8

HQs:United States×50Denmark×12Germany×3United Kingdom×3Netherlands×3France×2

Who they back

founder profiles across 8 portfolio companies

50%

solo founders

4 of 8 mapped founding teams

Founding team size:solo founder×42 founders×33 founders×1

Investments · 120 tracked

founders shown can be your intro path

By year:2026 · 8 2025 · 9 2024 · 8 2023 · 9 2022 · 8 2021 · 11 2020 · 3 2019 · 2 2016 · 1 2015 · 160 dated

AnaptysBioanaptysbio.com inNASDAQ: ANABJul 2015

AnaptysBio manages the financial collaborations from Jemperli (with GSK) and imsidolimab (with Vanda), operating a virtual model focused on protecting and returning royalty and milestone value to stockholders.

BiotechSan Diego, US

Robert Hoffman(Executive Officer)inMarco Londei(Executive Officer)inHamza Suria(Executive Officer, Director)inDaniel Faga(President, CEO, and Director)inChristopher Murphy(CFO)

BoardCarol Gallagher(Director)

Co-investorsBioBrit Frazier Life Sciences Biotechnology Value Fund Norwest Venture Partners

Avalyn Pharma Incavalynpharma.com inNASDAQ: AVLNApr 2026 · $300M

Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.

BiotechHealthtech

Lyn Baranowski(CEO)in

Co-investorsAndera Partners Catalio Capital Management, LP F-Prime Capital InVivium Capital Norwest Venture Partners RiverVest Venture Partners +9 more

Bolt Biotherapeuticsboltbio.com in 𝕏NASDAQ: BOLTFeb 2019 · $54M

Bolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer.

BiotechHealthtechMedical DevicesSan Francisco, US

Dr. Edgar G. Engleman(Founder)

Co-investorsPfizer Venture Investments RA Capital Samsara BioCapital Sofinnova Ventures Vivo Capital Nan Fung Life Sciences +3 more

Damora TherapeuticsNASDAQ: DMRA

Damora Therapeutics is a preclinical-stage biotechnology company that discovers and develops therapeutic candidates, including DMR-001, DMR-002, and DMR-003, with the goal of advancing treatments through investigational drug applications and clinical trials.

BiotechCopenhagen, US

Garrett Winslow(Executive Officer)in Lori Firmani(Executive Officer)inHans T. Schambye(Executive Officer, Director)Jennifer Jarrett(President, Chief Executive Officer and Director)inBecker Hewes(Chief Medical Officer)Sherwin Sattarzadeh(Chief Operating Officer)

Co-investorsAccess Biotechnology BAM Elevate Bay City Capital Commodore Capital EIR Ventures Forbion +6 more

Disc Medicinediscmedicine.com in 𝕏NASDAQ: IRONSep 2021 · $90M

Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.

BiotechHealthtech

John Quisel(Chief Executive Officer)in Jean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)in Pamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in

Co-investorsAccess Biotechnology Atlas Venture Bain Capital Life Sciences Foresite Capital Frazier Life Sciences OrbiMed +6 more

Edgewise Therapeuticsedgewisetx.com in 𝕏NASDAQ: EWTX

Edgewise Therapeutics discovers and develops small molecule medicines targeting muscle proteins to treat neuromuscular and cardiac diseases, including sevasemten for muscular dystrophies and EDG-7500 for cardiomyopathy, leveraging a proprietary drug discovery platform based on muscle physiology and high-throughput functional assays.

BiotechDigital HealthBoulder, US

Kevin Koch(Executive Officer, Director)in Alan Russell(Director)in Badreddin Edris(Director and Co-Founder)inKenneth Harrison(Director)

Board Peter Thompson(Director)inJonathan Root(Director)in

Co-investorsBoulder Ventures Foresite Capital OrbiMed US Venture Partners Deerfield Management Company

Harmony Biosciencesharmonybiosciences.com in 𝕏NASDAQ: HRMY

Harmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases.

BiotechHealthtechMedical DevicesNorthbrook, US

Jeffrey Aronin(Director)in Jeffrey M. Dayno, M.D.(President and Chief Executive Officer)inPatrick Morris(Secretary and Treasurer)inRobert Repella(Director and Chief Executive Officer)Darien Parhad(Chief Financial Officer)

Board Aaron Royston(Director)in

Co-investorsAisling Capital Paragon Biosciences LLC Valor Equity Partners venBio Partners venBio Global Strategic Vivo Capital

Hemab Therapeuticshemab.com in 𝕏NASDAQ: COAG

Hemab develops targeted therapies for bleeding and clotting disorders such as Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease, and heavy menstrual bleeding.

BiotechDigital HealthHealthtechMedical Devices

Co-investorsAccess Biotechnology Avoro Capital Advisors HealthCap Sofinnova Partners Avoro Ventures RA Capital

MapLight TherapeuticsNASDAQ: MPLT

MapLight Therapeutics is a biopharmaceutical company developing targeted treatments for central nervous system disorders through a platform designed to modulate neural circuits implicated in disease.

BiotechRedwood City, US

Anatol Kreitzer(Executive Officer)Kristopher Hanson(Executive Officer)Erin Foff(Executive Officer)inJames Lillie(Executive Officer)Jonathan Gillis(Executive Officer)inVishwas Setia(Executive Officer)in

Co-investorsAvego BioScience Capital Forbion

Mirum Pharmaceuticalsmirumpharma.com in 𝕏NASDAQ: MIRM

Mirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases.

BiotechHealthtechSan Diego, US

Chris Peetz(Co-founder & Chief Executive Officer)in Eric Bjerkholt(Executive Officer)in Peter Radovich(Executive Officer)in

Board Patrick Heron(Director)inMichael Grey(Director)Timothy Walbert(Director)

Co-investorsChiesi Ventures Frazier Life Sciences New Enterprise Associates (NEA)Pappas Capital RiverVest Venture Partners Deerfield Management Company +2 more

Nkarta, Inc.nkartatx.com inNASDAQ: NKTXAug 2019

Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments.

BiotechHealthtechSouth San Francisco, US

Paul Hastings(Executive Officer, Director)inPaul H.inMatthew Plunkett(Executive Officer)inPaul J. Hastings(Chief Executive Officer)in

BoardMichael Dybbs(Director)Jill Carroll(Director)in

Co-investorsNew Enterprise Associates (NEA)RA Capital Samsara BioCapital SR One Capital Management Amgen Ventures Logos +1 more

Onkure Therapeutics Inconkuretherapeutics.com in 𝕏NASDAQ: OKUR

OnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies.

BiotechDigital HealthHealthtechMedical DevicesBoulder, US

Jason Leverone(Executive Officer)inSamuel Agresta(Executive Officer)in Dylan Hartley(Executive Officer)inWendy Johnson(Executive Officer)Nicholas A. Saccomano(President and Chief Executive Officer and Director)

BoardIsaac Manke(Director)in

Co-investorsAccess Biotechnology Boulder Ventures RiverVest Venture Partners Abingworth ACORN BIOVENTURES New Enterprise Associates (NEA)

Praxispraxismedicines.com in 𝕏NASDAQ: PRAX

Praxis Precision Medicines is a central nervous system precision neuroscience biopharmaceutical company developing therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance, with a pipeline spanning movement disorders and epilepsy.

BiotechDeep TechHealthtechBoston, US

Steve Petrou(Co-Founder, President of Research & Development)in Kiran Reddy(Executive Officer, Director)inMarcio Souza(President & Chief Executive Officer)in

BoardNicholas G. Galakatos(Director)

Co-investorsAvoro Capital Advisors Capria Ventures OCV Partners Alameda Research APOLLO PROJECTS Blackstone +6 more

Recursion (NASDAQ: RXRX)recursion.com in 𝕏NASDAQ: RXRX

Recursion applies computational and data-driven approaches to biological science, aiming to accelerate drug discovery and develop new treatments.

AI & Machine LearningBiotechData & InfrastructureDeep TechMedical DevicesSalt Lake City, US

Chris Gibson(Co-founder, Chairman of the Board)in Blake C. Borgeson(Executive Officer, Director)inDean Y. Yi(Executive Officer, Director)Najat Khan(Chief Executive Officer)in

Co-investorsDCVC (Data Collective)Lux Capital Baillie Gifford Air Street Capital Amplify Partners Catalio Capital Management, LP +14 more

Spruce Biosciencessprucebiosciences.com in 𝕏NASDAQ: SPRB

Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B).

BiotechHealthtechSouth San Francisco, US

Javier Szwarcberg(Executive Officer, Director)in Samir Gharib(Executive Officer)inRICHARD KING(Executive Officer, Director)inJavier Szwarcberg, M.D., M.P.H.(Chief Executive Officer)in

BoardSimpson Camilla(Director)Tiba Aynechi(Director)in

Co-investorsAisling Capital HealthCap RiverVest Venture Partners Abingworth Norwest Venture Partners Omega Funds +1 more

Biomasonbiomason.com in 𝕏Feb 2022✓ verified

Biomason uses biotechnology to grow biocement, producing concrete and tile products by using bacteria to bind natural materials as an alternative to Portland cement, aimed at concrete producers and the construction industry.

BiotechClimate TechConstruction TechNew MaterialsResearch Triangle Park, US

Ginger K. Dosier(Executive Officer, Director)inMichael F. Noel(Director)John M. Dosier(Executive Officer)

Board seat Anders Bendsen Spohr· per SEC Form D

Co-investorsCarbon Celesta Capital Celesta Capital

Acesion Pharma ApSacesionpharma.com in✓ verified

Acesion Pharma is a biotech company developing pharmaceutical treatments.

BiotechHealthtechMedical DevicesCopenhagen, DK

Ulrik Sørensen(COO & Co-founder)in Morten Grunnet(CSO & Co-founder)in Anders Gaarsdal Holst(CEO & CMO)inTorgeir Vaage(CFO)in

Co-investorsAlpha Wave Global Canaan Partners Broadview Ventures Global BioAccess Fund

Alentisalentis.ch in✓ verified

Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease.

AI & Machine LearningBiotechHealthtechMedical DevicesBasel, CH

Thomas Baumert(Founder)inMark Pruzanski(Chief Executive Officer)in Luigi Manenti(Chief Medical Officer)inJon Freve(Chief Financial Officer)inBryan Yoon(General Counsel and Chief Administrative Officer)inAditya Venugopal(Chief Business Officer)in

Co-investorsAvego BioScience Capital BioMedPartners Frazier Life Sciences Jeito Capital Longitude Capital OrbiMed +5 more

Altasciencesaltasciences.com in✓ verified

Altasciences operates a drug development platform that integrates nonclinical research, bioanalysis, manufacturing, and Phase I/II clinical execution to compress early-stage drug development timelines from industry standards of 27–51 months to as little as 18 months.

BiotechDeep TechEnterprise SoftwareHealthtechMedical DevicesLaval, CA

Marie-Hélène Raigneau(Chief Executive Officer)inCatherine Konidas(Chief Administrative Officer)inDr. Beatrice Setnik(Chief Scientific Officer)Dr. Gaetano Morelli(Executive Vice President Medical Affairs, Chief Medical Officer)Steve Mason(Co-Chief Operating Officer)in Robert Sabelli(Co-Chief Operating Officer)in

Co-investorsKilmer Group Signet Healthcare Partners

Amassamass.tech in✓ verified

Amass operates an agentic data platform that unifies over 500 million scientific documents — including research literature, patents, clinical trials, regulatory filings, and web sources — into a single engine that returns answers cited to their source.

AI & Machine LearningBiotechData & Infrastructure

Alexander Junge(Co-Founder & CTO)inHenrik Jensen(Co-Founder & CEO)in

Co-investorsGiant Ventures Global Llp Kost Capital

AMSilkamsilk.com inSep 2025✓ verified

AMSilk produces biotech-derived silk protein yarns for textile applications including fashion, accessories, and automotive interiors, using fermentation-based bioprocessing instead of traditional sericulture.

Advanced ManufacturingBiotechCircular EconomyCleantechNew MaterialsMunich, DE

Co-investorsAthos MIG Capital AG

AnaCardioanacardio.com✓ verified

AnaCardio is a Swedish clinical-stage biopharmaceutical company developing novel drugs to treat heart failure, with its lead program AC01 in phase 1b/2a clinical development.

BiotechHealthtechMedical DevicesStockholm, SE

Lars H. Lund(Founder)

Co-investors3B Future Health Fund Industrifonden Pureos Bioventures Sound Bioventures

AvenCellavencell.com in 𝕏Oct 2024 · $112M✓ verified

AvenCell Therapeutics develops next-generation cell therapies for hard-to-treat cancers, including solid tumors, combining switchable universal CAR-T technology with a CRISPR/Cas9-based allogeneic platform.

BiotechLongevityMedical Devices

Andrew Schiermeier(Chief Executive Officer)in

Co-investorsBlackstone Life Sciences Eight Roads Ventures F-Prime Capital NYBC Ventures

Benchmark Geneticsbmkgenetics.com in 𝕏✓ verified

BMK Genetics develops breeding programs and genetic solutions for salmon farming, offering tailored genetics for both sea-based open net-pen systems and land-based recirculating aquaculture systems.

AgTechBiotechFoodTechBergen, NO

Kristian Botnen(CEO)in

Boostertxboostertx.com in✓ verified

Booster Therapeutics develops small-molecule medicines that directly activate the cell's 20S proteasome to restore protein quality-control and clear disease-causing proteins, using its structure-based DGRADX platform combining high-throughput screening, X-ray crystallography, and computational tools.

BiotechDeep TechLongevity

Diogo R. Feleciano(Co-Founder & CSO)inDarci J. Trader(Scientific Co-Founder / Advisor)João Ribas(Interim-CBO)in

Co-investorsApollo Health Ventures Korify Capital

Breyebreye.com in✓ verified

Breye Therapeutics is a biopharmaceutical company developing medicines for ophthalmologic and metabolic diseases, leveraging expertise in clinical development, manufacturing, and regulatory pathways.

BiotechMedical Devices

Ulrik Mouritzen(CEO)

Co-investorsSound Bioventures

Calliotxcalliotx.com in✓ verified

Callio Therapeutics develops next-generation dual-payload antibody-drug conjugates (ADCs) with differentiated payload and linker technologies for targeted cancer treatment.

BiotechMedical DevicesSeattle, US

Piers Ingram(President, Co-Founder)in Jerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)inZachary Hornby(Chief Executive Officer)

Co-investorsOmega Funds Frazier Life Sciences Jeito Capital Norwest Venture Partners

Chromologicschromologics.com inMar 2023✓ verified

Chromologics is a Danish biotech company that uses a precision fermentation platform to produce natural food colours, marketed to food and beverage manufacturers as an alternative to synthetic colourants.

BiotechFoodTechNew MaterialsCopenhagen, DK

Anders Odum(Founder)in Gerit Tolborg(Co-founder & CEO)inAnders Ødum(Co-founder & CTO)Klaus Bjerrum(CTO & Founder)inChristian H. Steffensen(CEO)in Jens Bergholdt(CFO)in

Co-investorsBlue Horizon Corporation Collateral Good Nordic Foodtech VC Doehler Ventures

Clever Care Health Planclevercarehealthplan.com in✓ verified

Clever Care is a culturally and linguistically sensitive Medicare Advantage health plan serving Southern California that integrates Eastern and Western medicine approaches.

HealthtechInsurTechSouthern California, US

Myong Sun Lee(Executive Officer, Director)Hiep Dinh Pham(Executive Officer, Director)Dave Firdaus(Executive Officer, Director)

Co-investorsNorwest Venture Partners Global Founders Capital GV (Google Ventures)AV8 Ventures Figure 8 Investments PruVen Capital Partners +1 more

Crystalystxcrystalystx.com in 𝕏✓ verified

Crystalys Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for gout, a chronic metabolic disease caused by elevated uric acid.

BiotechHealthtechMedical DevicesSan Diego, US

James Mackay(President & Chief Executive Officer)inNihar Bhakta(Chief Medical Officer)inAshwin Ram(Chief Operating Officer)inDeAnne Reid(Chief Administrative Officer)in

Co-investorsCatalys Pacific AN Venture Partners Frazier Life Sciences Lightstone Ventures Longwood Fund

Engimmune Therapeuticsengimmune.com in✓ verified

Engimmune develops soluble TCR therapeutic candidates using AI-guided innovation and protein engineering for oncology and immunotherapy applications.

AI & Machine LearningBiotechDeep Tech

Rodrigo Vazquez-Lombardi inSai Reddyin

Co-investorsPureos Bioventures

Esco Lifesciences Groupescolifesciences.com in 𝕏May 2021 · $265M✓ verified

Esco Lifesciences manufactures laboratory equipment, biopharma devices, and IVF medical equipment for clinical, research, and industrial laboratories across more than 100 countries.

Advanced ManufacturingBiotechHardwareHealthtechMedical DevicesSingapore, SG

Lim Lay Yew(Founder)inLow Yae Foong(Founder)

Co-investorsVivo Capital GIC

Expeditiontxexpeditiontx.com in✓ verified

Expedition Therapeutics is a drug development company focused on advancing therapeutic programs in areas such as CAR-T immunotherapy and oncology.

BiotechHealthtechMedical DevicesSan Francisco, US

Yi Larson(Founder and CEO)Geoff Gilmartin(Chief Medical Officer)Eric Hu(Chief Business Officer)

Co-investorsForbion Sofinnova Ventures Sanofi Ventures

LanzaTechlanzatech.com in 𝕏✓ verified

LanzaTech converts carbon-rich gases from industrial sources like steel mills and landfills into fuels and chemicals using synthetic biology.

Circular EconomyCleantechClimate Tech

Dr. Jennifer Holmgren(CEO)

Co-investorsActivant Capital Khosla Ventures Outset Ventures Qiming Venture Partners

MedGenomemedgenome.com in 𝕏✓ verified

MedGenome provides genetic and molecular diagnostic testing across areas including reproductive care, rare hereditary conditions, oncology, and infectious diseases, and operates a CAP-accredited multiomics laboratory with high-throughput sequencing and a proprietary analytics platform.

BiotechDigital HealthHealthtechMedical DevicesBangalore, IN

Co-investorsSofina Peak XV Partners

MinervaXminervax.com inOct 2023✓ verified

MinervaX is a biotech company developing prophylactic vaccines, with therapeutic focus areas including immunology and infectious disease.

BiotechHealthtech

PerBengt(CSO)

Co-investorsAdjuvant Capital Industrifonden OrbiMed Pureos Bioventures Sanofi Ventures Sunstone Capital +2 more

NMD Pharmanmdpharma.com in 𝕏Nov 2023 · $81.3M✓ verified

NMD Pharma is a clinical-stage biotech company developing first-in-class small-molecule therapies that selectively target skeletal muscle to treat rare neuromuscular diseases and age-related conditions.

BiotechDeep TechHealthtechMedical DevicesAarhus, DK

Co-investorsJeito Capital Roche Venture Fund Inkef

Northsea Therapeuticsnorthseatherapeutics.com in✓ verified

NorthSea Therapeutics is a clinical-stage biopharmaceutical company developing oral fatty acid-derived therapies for liver and metabolic diseases, including intestinal failure-associated liver disease (IFALD), severe hypertriglyceridemia, and MASH.

BiotechDigital HealthHealthtech

Co-investorsNew Science Ventures venBio Partners Ysios Capital BGV BioGeneration Ventures Forbion +1 more

Revagenixrevagenix.com inJan 2024✓ verified

Revagenix is a precision-therapeutics company that develops drugs for serious chronic diseases, starting from the underlying biology and unmet clinical needs.

BiotechDeep TechHealthtechMedical Devices

Ryan Cirz(Co-founder & CEO)in Andrew McCandlish(Co-founder & COO)inPeter Smith(Chief Scientific Officer)inDaniel Cloutier(VP, Development)in

Co-investorsTenmile

Route 92route92medical.com in 𝕏Sep 2024 · $50M✓ verified

Route 92 Medical develops medical devices and procedural solutions for patients undergoing neurovascular intervention.

BiotechHealthtechMedical DevicesSan Francisco, US

Dr. Chou(Founder, Chief Executive Officer)Dr. Joey English(Chief Medical Officer)

Co-investorsThe Vertical Group US Venture Partners Norwest Venture Partners Sectoral Asset Management U.S. Venture Partners

Sonionsonion.com in✓ verified

Sonion designs and manufactures miniaturized audio components and solutions for hearing aids, including microphones, receivers, RIC systems, and sensors.

Deep TechHardwareHealthtechMedical DevicesRoskilde, VN

Co-investorsAltor

The Ritedose Corporationritedose.com in✓ verified

Ritedose is a contract development and manufacturing organization (CDMO) that produces generic and specialty medications using advanced data analysis and custom technology solutions.

Advanced ManufacturingBiotechHealthtechMedical DevicesColumbia, US

Jody Chastain(Chief Executive Officer)in

Co-investorsOlympus Partners

THEVAtheva.com✓ verified

THEVA manufactures high-temperature superconductor wire and related components for industrial, power transmission, and renewable energy applications.

Advanced ManufacturingDeep TechEnergyNew MaterialsGermany, DE

Co-investorsBayern Kapital EnBW New Ventures GmbH Target Partners

Verana Healthveranahealth.com in 𝕏✓ verified

Verana Health aggregates de-identified clinical data from a network of over 20,000 physicians in ophthalmology, urology, and neurology to power real-world evidence, clinical trial enablement, and quality reporting for pharmaceutical companies and healthcare providers using AI and machine learning.

AI & Machine LearningData & InfrastructureDigital HealthHealthtechSan Francisco, US

Mark Blumenkranz, MD(Co-Founder, Verana Health and Lagunita Biosciences)Sujay Jadhav(Chief Executive Officer)in

Co-investorsBreyer Capital Tech Council Ventures Valspring Capital Define Ventures

ZELPzelp.co in✓ verified

ZELP develops technology to measure and reduce methane emissions from the livestock industry.

AgTechClimate TechImpact & Social GoodIoT

Francisco(Co-Founder, CEO)inPatricio(Co-Founder, Chairman of the Board)

Co-investorsCollaborative Fund Danone Manifesto Venture Starlight Ventures

Availity inJul 2021

HealthtechJacksonville, US

Nathan W. Eastman(Chief Financial Officer, Treasurer)inChristopher Hunter(Director)Steve Betts(Director)Earnie Franklin(Director)Aaron Gani(Director)Carl McDonald(Director)

Board seat Abhijeet Lele· per SEC Form D

Co-investorsFrancisco Partners

Genomaticagenomatica.com in 𝕏Aug 2021 · $118M

Genomatica (Geno) develops biotechnology processes to produce bio-based chemicals and materials—such as 1,4-butanediol (BDO), butylene glycol for cosmetics, and plant-based nylon—as alternatives to fossil-fuel-derived inputs.

BiotechCircular EconomyCleantechClimate TechNew MaterialsSan Diego, US

Christophe Schilling(Co-founder (former CEO))inBernhard Palsson(Co-founder)Carlos A. Cabrera(Executive Chairman)in John G. Gugel(Chief Executive Officer)in Tom McDonald(SVP, Finance & Chief Financial Officer)inNelson Barton(SVP, Research and Development)in

Board seat Anders Bendsen Spohr· per SEC Form D

Co-investorsThule Investments VantagePoint Capital Partners Casdin Capital Draper Fisher Jurvetson (DFJ)Mohr Davidow Ventures

MycoWorksmycoworks.com in 𝕏Apr 2022

MycoWorks produces Reishi, a premium biomaterial made from Fine Mycelium, used as a sustainable leather alternative in furniture, design, and automotive products.

BiotechCircular EconomyNew MaterialsEmeryville, US

Philip Ross(Director)inMichael Lindheim(Executive Officer)Matthew Scullin(Executive Officer, Director)in

BoardKiersten Stead(Director)inThomas Grotkjaer(Director)

Board seat Anders Bendsen Spohr· per SEC Form D

Co-investorsDCVC (Data Collective)Hemisphere Ventures LLC Wireframe Ventures 8VC AgFunder DCVC Bio +5 more

Adcendo ApSadcendo.com

Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.

BiotechMedical Devices

Co-investorsVida Ventures HealthCap Jeito Capital OrbiMed Pontifax Venture Capital RA Capital +2 more

Antag Therapeuticsantagtherapeutics.com inDec 2024 · $84M

Antag Therapeutics develops GIP receptor antagonist therapies for obesity, diabetes, and overweight patients.

BiotechHealthtechCopenhagen, DK

Jens Juul Holst(Founder)Mette Rosenkilde(Founder)in

Co-investorsBroadview Ventures SR One Capital Management Versant Ventures

Anywhereanywhere.camDec 2023 · $54.7M

A retailer that sells security and monitoring cameras along with related accessories, offering different options for single or multi-location surveillance needs.

E-commerceHardware

Co-investorsGreater Colorado Venture Fund General Atlantic Hercules Capital, Inc.New Enterprise Associates (NEA)SoftBank Group SoftBank Vision Fund +1 more

Arcellxarcellx.com inApr 2021 · $115M

Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer.

BiotechHealthtechGaithersburg, US

Han Lee(Executive Officer)Rami Elghandour(Executive Officer, Director)in

Board Jill Carroll(Director)inAli Behbahani(Director)in Derek Yoon(Director)in Tiba Aynechi(Director)in

Co-investorsLG Technology Ventures New Enterprise Associates (NEA)Quan Capital Samsara BioCapital Sixty Degree Capital Solasta Ventures +5 more

Asgardasgard.ai in 𝕏Nov 2021

Asgard provides sales intelligence and intent detection data to B2B companies, identifying qualified prospects and their specific needs for targeted sales outreach and account-based marketing campaigns.

AI & Machine LearningData & InfrastructureEnterprise SoftwareSales TechParis, FR

Co-investorsTechstars Boehringer Ingelheim Venture Fund Industrifonden Robot Ventures

Asgard Therapeuticsasgardthx.com in 𝕏Nov 2021

Asgard Therapeutics develops direct cell reprogramming technologies that convert cancer cells into dendritic cells to restore anti-cancer immune responses.

AI & Machine LearningBiotechHealthtechMedical DevicesLund, SE

Cristiana Pires(Co-founder and CEO)in Fábio Rosa(Co-founder and VP of Research)in Filipe Pereira(Co-founder and Head of Innovation)in

Co-investorsIndustrifonden LU Innovation Boehringer Ingelheim Venture Fund

Augustine Therapeuticsaugustinetx.com in

Augustine Therapeutics is a biotech company developing HDAC6-targeted therapies for peripheral neuropathies such as Charcot-Marie-Tooth disease and chemotherapy-induced peripheral neuropathy, as well as neurodegenerative disorders like ALS.

BiotechMedical Devices

Co-investorsAdBio partners Jeito Capital PMV V-Bio Ventures Asabys Partners Newton Biocapital

Bactolifebactolife.com in

Bactolife develops Binding Proteins for use in functional foods for humans and in animal feed, aimed at supporting healthy digestion and livestock health.

AgTechBiotechFoodTech

Co-investorsCross-Border Impact Ventures

BBI Solutionsbbisolutions.com

BBI Solutions provides reagents and biochemical products for in vitro diagnostics and life sciences teams, supporting assay development and diagnostic test manufacturing.

Advanced ManufacturingBiotechHealthtechMedical Devices

Alexander Socarrás(Group CEO)in

BioGeneration Venturesbiogenerationventures.com

BioGeneration Ventures (BGV) is the early-stage arm of the Forbion-BGV platform of funds, investing in and supporting biotech and life sciences companies across their stages of development.

BiotechHealthtechNaarden, NL

Co-investorsBOM KfW Capital European Investment Fund KfW

Biosyntiabiosyntia.com inOct 2022

Biosyntia is a Copenhagen-based industrial biotech company that uses strain engineering and fermentation to produce sustainable, bio-based active ingredients like vitamin B7, replacing petrochemical-derived alternatives for cosmetics and nutrition markets.

Copenhagen, DK

Co-investorsEuropean Circular Bioeconomy Fund Sofinnova Partners

Bluejay Therapeutics inMay 2024 · $182Macquired by Mirum Pharmaceuticals · Dec 2025 · $620M

Healthcare company acquired by Mirum Pharmaceuticals, a former RiverVest portfolio company.

San Mateo, US

Keting Chu(Executive Officer, Director)inDajun Yang(Director)Nancy Hong(Director)inAlon Lazarus(Director)William J. Rutter(Director)Ting Jia(Director)

Co-investorsFrazier Life Sciences RA Capital RiverVest Venture Partners Frazier Healthcare Partners HBM Healthcare Investments T. Rowe Price +1 more

Cirius Therapeuticsciriustx.com

Cirius Therapeutics is a clinical-stage pharmaceutical company developing therapies for patients with chronic metabolic diseases driven by insulin resistance, including Type 2 Diabetes and obesity.

BiotechDigital HealthGrand Rapids, US

Jerry Callahan(Executive Officer)Brian Farmer(Executive Officer)inRobert Baltera(Executive Officer, Director)Howard Dittrich(Executive Officer)

BoardMichael Jandernoa(Director)Mark Olesnavage(Executive Officer)

Co-investorsFrazier Healthcare Partners

Claris Bioclarisbio.com inJul 2026

Claris Bio develops biologic therapies for sight-threatening eye diseases, with a current focus on bringing CSB-001, a novel treatment for patients with limbal stem cell deficiency, through clinical development and to market.

BiotechHealthtechMedical DevicesJersey City, US

Clarke Atwell(Co-Founder and Chief Operating Officer)inHenry Rath(Executive Officer)Susan Orr(Executive Officer)inStephen Brady(Executive Officer, Director)Michael Dybbs(Director)Matt Hobson(Director)

Co-investorsCatalio Capital Management, LP RA Capital Sofinnova Ventures Catalio Capital Management Samsara BioCapital

Clasp Therapeuticsclasptx.com in

Clasp Therapeutics develops off-the-shelf precision T cell engagers (its proprietary pHLАre molecules) that target mutant peptide-HLA complexes displayed on cancer cells, directing T cells to destroy tumors carrying common driver mutations such as KRas.

BiotechHealthtechCambridge, US

Co-investorsCatalio Capital Management, LP Cure Ventures Vivo Capital Catalio Capital Management Third Rock Ventures

Coave Therapeuticscoavetx.com in

Coave Therapeutics develops targeted gene therapy vectors using its proprietary ALIGATER platform to deliver therapeutic genes to specific tissues with improved safety and precision.

BiotechDeep TechHealthtechMedical DevicesParis, FR

Co-investorsFund+Kurma Partners Seroba Life Sciences V-Bio Ventures Bpifrance Invus +1 more

Commit Biologicscommitbio.com in

Commit Biologics develops a complement-targeted drug discovery platform and antibody-based therapeutics for oncology, autoimmune diseases, and infectious disease indications.

BiotechHealthtechMedical DevicesAarhus, DK

Dennis(COO & Co-founder)Nick(Head of Discovery & Co-founder)Mikael(Head of Platform Technology & Co-founder)Heidi(Head of Drug Screening & Co-founder)Thomas(CEO)

Co-investorsKorys Bioqube Ventures

Complement Therapeuticscomplementtx.comSeed · Feb 2022 · $6M

Complement Therapeutics is a clinical-stage biotechnology company developing gene therapies for complement-mediated diseases, with a lead AAV-based candidate (CTx001) for Geographic Atrophy secondary to Age-related Macular Degeneration.

BiotechDigital HealthHealthtechMedical DevicesMunich, DE

Rafiq Hasan(CEO and Managing Director)in Muhammad Ali Memon(Chief Medical Officer)in

Co-investorsCambridge Innovation Capital Hadean Ventures Seroba Life Sciences BGV BioGeneration Ventures Forbion +2 more

Coultreoncoultreon.com inApr 2026 · $125M

Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.

AI & Machine LearningBiotech

Pierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)in Marie De Vulder(Chief Legal Officer Co-founder)in Guy Peeters(Chief Financial Officer Co-founder)in John-Paul Gallivan(Head of Development Co-founder)in Fabrice Kolb(Head of Immunology Co-founder)inPieter Peeters(Operating & Technology Officer Co-founder)in

Co-investorsLongwood Fund Sofinnova Ventures BAM Elevate Finchley Healthcare Ventures Forbion Luma Group +1 more

Cyteir Therapeuticscyteir.com in 𝕏Feb 2021 · $80M

Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters.

BiotechHealthtechCambridge, US

Kevin Mills(Executive Officer, Director)inRonald Goldstein(Executive Officer)in Donald Corcoran(Executive Officer, Director)in Markus Renschler(Director)in

BoardTimothy Romberger(Director)Barry Mills(Director)

Co-investorsDroia Ventures Lightstone Ventures OUP (Osage University Partners)Ally Bridge Group De Novo Ventures Janus Henderson Investors +3 more

Doctor Anywheredoctoranywhere.com inDec 2023

Doctor Anywhere is a technology-driven healthcare company that provides medical care to patients through online and in-person channels.

Digital HealthHealthtechMental Health

Co-investorsOSK Ventures International Square Peg Capital

Draupnirdraupnir.bio inJul 2024

Draupnir Bio develops targeted protein degradation therapies using sortilin-based lysosome targeting chimeras to clear extracellular and membrane-bound protein aggregates in proteinopathies.

BiotechDeep TechMedical DevicesCopenhagen, DK

Simon Glerup(Professor)inCamilla Gustafsen(Professor)inPeder Søndergaard Madsen(Professor)Peter Seeberger(Professor)

Co-investorsGilde Healthcare Inkef MC Healthcare Ventures

Droia Venturesdroiaventures.com inJan 2026

Droia Ventures is a specialist venture capital firm investing globally in early-stage drug development companies focused on therapeutics for oncology and genetic disease.

BiotechLeuven, BE

Co-investorsClavystBio Frazier Life Sciences LifeArc Ventures

Elo Lifeelolife.com in 𝕏

Elo develops plant-based food ingredients and technologies to enhance nutritional value, taste, and climate resilience in everyday foods.

AgTechBiotechClimate TechFoodTechNew MaterialsDurham, US

Todd Michele Fite(Executive Officer)inMatthew Todd Rands(Executive Officer, Director)Chloe Pavely(Executive Officer)in Matt DiLeo(Director)in Paul Boyer(Executive Officer)in

Co-investorsDCVC (Data Collective)Accelr8 DCVC Bio KdT Ventures

Extracellularextracellular.com inMay 2025 · $130M

Extracellular is a biomanufacturing company that helps cell-based product developers in cultivated meat, plant cell culture, and bioactives accelerate discovery, overcome production challenges, and commercialize their products.

Advanced ManufacturingBiotechFoodTechNew Materials

Will Milligan(CEO & Founder)in

Co-investorsBig Idea Ventures FFF Newland Syndicate Unruly Capital 5AM Ventures Agent Capital +8 more

FIRE1fire1foundry.com in 𝕏Mar 2023 · $120M

FIRE1 develops NORM, an implantable sensor placed in the inferior vena cava to directly measure fluid volume in heart failure patients, paired with a self-management platform to help patients engage with their own care.

Digital HealthHardwareMedical DevicesDublin, IE

Co-investorsAndera Partners Lightstone Ventures Longitude Capital New Enterprise Associates (NEA)Gilde Healthcare Gimv +5 more

Genomegenomemedical.com in 𝕏

Genome Medical provides telehealth-enabled genetic services, including genetic counseling, genetic testing, and clinical trial matching, with a focus on individuals with rare conditions.

BiotechDigital HealthHealthtech

Mark Sylvester(Chief Financial Officer)in Andrew Warner(Vice President, Product)in Monica Zarb(Vice President, Business Development)in Durand Van Arnem(Vice President, Engineering)inAlan Rope(Medical Director)in

Co-investorsCanaan Partners Dreamers VC Echo Health Ventures GV (Google Ventures)Illumina Ventures Kaiser Permanente Ventures +7 more

GlycoEraglycoera.com in 𝕏Series B · May 2025 · $130M

GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs.

BiotechHealthtechNewton, US

Ganesh V. Kaundinya(President & CEO)in

Co-investors5AM Ventures Catalio Capital Management, LP LifeArc Ventures Roche Venture Fund Sixty Degree Capital Sofinnova Partners +1 more

Hoba Therapeutics ApShobatherapeutics.comDec 2023

Danish biotech developing non-opioid restorative treatments for chronic pain, hearing loss and sensory neuron disorders.

Co-investorsEIR Ventures Indaco Venture Partners Medical Incubator Japan K.K.

HPNowhpnow.eu inSep 2023

HPNow produces hydrogen peroxide (Peroxide UltraPure) on-site through a patented electrochemical process that converts water, electricity, and air into low-concentration, high-purity peroxide for water treatment.

AgTechCircular EconomyCleantechHardwareNew Materials

Co-investorsAP Ventures Evonik Venture Capital GmbH

HST Pathwayshstpathways.com in 𝕏Jun 2026

HST Pathways provides an all-in-one technology platform for ambulatory surgery centers (ASCs) that integrates clinical, financial, and operational management.

Digital HealthEnterprise SoftwareHealthtechSaaS

Gavin(Founder)

Co-investorsBain Capital Tech Opportunities Blue Hour Ventures Bain Capital

Hummingbirdhummingbird-tech.comMay 2021

OLG Machinery, founded in 2008, trades new and certified used industrial spare parts and machinery, serving U.S. companies operating across North and South America with a focus on Mexico.

Advanced ManufacturingB2B MarketplacesLogistics & Supply Chain

Co-investorsOxford Investment Opportunity Network (OION)Ally Bridge Group Altium Capital Amgen Ventures Droia Ventures Frazier Healthcare Partners +2 more

Hummingbird Biosciencehummingbirdbioscience.com in 𝕏May 2021

Hummingbird Bioscience is a precision biotherapeutics company developing a pipeline of novel targeted therapies for cancer, using proprietary drug discovery technologies and platforms.

AI & Machine LearningBiotechDeep TechHealthtech

Piers Ingram(Chief Executive Officer, Co-Founder, Executive Director)in Jerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)inKonrad Paszkiewicz(Chief Technology Officer)inKwek Kon Yew(Chief Medical Officer)Dipti Thakkar(Chief Operating Officer)in

Co-investorsAltium Capital ClavystBio Decheng Capital Droia Ventures Frazier Life Sciences Kiwoom Investment +5 more

Inspirnainspirna.com in 𝕏Jul 2022 · $50M

Inspirna is a clinical-stage biopharmaceutical company developing novel cancer drugs that target previously undruggable drivers of metastasis using its proprietary miRNA-DRIVEr platform.

BiotechHealthtechMedical DevicesNew York, US

Sohail Tavazoie(Co-Founder & Chair of Scientific Advisory Board)Masoud Tavazoie(Co-Founder & Advisor)in

Co-investorsSofinnova Partners Vivo Capital Sands Capital Ventures Start Capital

Inventivainventivapharma.com in 𝕏

Inventiva is a clinical-stage biopharmaceutical company developing drug candidates, with a focus on liver and other diseases.

BiotechMedical Devices

Co-investorsEuropean Investment Bank Andera Partners Claret Capital Partners New Enterprise Associates (NEA)Samsara BioCapital Sofinnova Partners +1 more

Invetxinvetx.com

Boston, US

Jurgen Horn(Executive Officer, Director)

BoardPhilip Austin(Director)in

Co-investorsF-Prime Capital GV (Google Ventures)Anterra Capital Casdin Capital Eight Roads Ventures

Kebotixkebotix.com in 𝕏

Kebotix uses artificial intelligence, machine learning, and laboratory automation to discover and develop new materials and molecules.

AI & Machine LearningDeep TechNew MaterialsCambridge, US

Dennis Sheberla(Executive Officer)inSemion Saykin(Executive Officer)Alan Aspuru-Guzik(Executive Officer)inAshish Kulkarni(Executive Officer, Director)in

BoardTong Hui(Director)Andrew Krowne(Director)in

Co-investorsArcTern Ventures Bantam Group Flybridge Capital Partners One Way Ventures Propagator Ventures Safar Partners +4 more

Kivu Biosciencekivubioscience.com inOct 2024 · $92M

Kivu Bioscience develops antibody-drug conjugate (ADC) therapeutics in clinical development, advancing a pipeline of cancer treatments through strategic partnerships and collaborations.

BiotechDeep TechHealthtechMedical Devices

Mohit Trikha(CEO)in Sophia Randolph(Chief Medical Officer)in

Co-investorsBOM HealthCap M Ventures Red Tree Venture BioGeneration Ventures

LimmaTech Biologicslmtbio.com inacquired by Lilly

LimmaTech develops vaccine technologies and programs designed to combat antimicrobial-resistant pathogens and prevent severe infections.

AI & Machine LearningBiotechHealthtechMedical Devices

Co-investorsAdjuvant Capital Andera Partners Tenmile

MDLIVEmdlive.com inSep 2020 · $50M

MDLIVE is a telehealth service offering 24/7 virtual medical appointments by phone or video with a national network of board-certified doctors, dermatologists, psychiatrists, and therapists.

Digital HealthHealthtechMental Health

Co-investorsPerot Jain Sixth Street Health Velocity Capital Industry Ventures Kayne Anderson Capital Advisors

Metagenomimetagenomi.co in 𝕏Jan 2022 · $175M

Metagenomi Therapeutics is an in vivo genome editing company that uses genetic material sourced from natural environments (metagenomics) to develop a toolbox of editing tools for deletion, integration, and correction of genetic mutations.

BiotechDeep TechMedical DevicesBerkeley, US

Brian Thomas(Executive Officer, Director, Promoter)in

Board Andrew Farquharson(Director)inJak Knowles(Director)

Co-investorsCatalio Capital Management, LP RA Capital Sozo Ventures Agent Capital Frazier Life Sciences Humboldt +5 more

Myricx Biomyricxbio.com in

Myricx Bio is a biotech company developing antibody drug conjugates (ADCs) based on N-myristoyltransferases (NMT) inhibitors for cancer treatment.

BiotechMedical DevicesLondon, GB

Co-investorsBrandon Capital Partners Sofinnova Partners Abingworth

Newleos Therapeuticsnewleostherapeutics.com inFeb 2025 · $93.5M

BiotechBoston, US

David Donabedian(Executive Officer, Director)in Robert Hadfield(Executive Officer)in John McCabe(Executive Officer)in

Board Christoph Westphal(Director)Ming Cheah(Director)inRaymond Camahort(Director)

Co-investorsDCVC (Data Collective)DCVC Bio Longwood Fund

Novo Nordisknovonordisk.com in 𝕏

Novo Nordisk is a pharmaceutical company that develops and markets treatments for conditions including diabetes, obesity/weight management, and haemophilia, with products such as GLP-1 therapies.

BiotechHealthtechCopenhagen, DK

Maziar Mike Doustdar in

Co-investorsHM Venture Partners

Novonesisnovonesis.com in

Novonesis develops biological solutions for agriculture, animal feed, food production, and consumer products, helping customers improve crop yields, product quality, and sustainability.

AgTechBiotechClimate TechFoodTechCopenhagen, DK

Oxboxb.com in

Oxford Biomedica is a biopharmaceutical contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, lentiviral vector technologies, and bioprocessing solutions.

Advanced ManufacturingBiotechDeep TechHealthtechMedical DevicesOxford, GB

Dr. Frank Mathias(Chief Executive Officer)inDr. Lucinda Crabtree(Chief Financial Officer)

BoardDr. Roch Doliveux(Non-Executive Chair)

Co-investorsOberland Capital

Qurequre.ai in 𝕏Mar 2022 · $40M

Qure.ai builds deep learning and AI software to detect and manage diseases such as lung cancer, tuberculosis, pediatric TB, and stroke, with several FDA-cleared solutions.

AI & Machine LearningDigital HealthHealthtechMedical Devices

Co-investorsCrane Venture Partners Lightspeed Venture Partners HealthQuad Kae Capital MassMutual Ventures Merck Global Health Innovation Fund +1 more

Rapptarappta-therapeutics.comOct 2020

Rappta Therapeutics develops small molecule compounds that reactivate protein phosphatase 2A (PP2A) to treat cancer by restoring the enzyme's tumor suppressor function.

AI & Machine LearningBiotechHealthtechMedical Devices

Co-investorsAdvent Life Sciences Novartis Venture Fund

Raytherapeuticsraytherapeutics.com

Ray Therapeutics develops optogenetics gene therapy treatments for blinding diseases using advanced biotechnology.

BiotechDigital HealthHealthtechMedical Devices

Paul Bresge(Co-founder & Chief Executive Officer)

Co-investorsNorwest Venture Partners

Reunion Neurosciencereunionneuro.com in 𝕏Sep 2025 · $103M

Reunion Neuroscience is a clinical-stage biopharmaceutical company developing serotonergic psychedelic therapies for mental health conditions such as postpartum depression, adjustment disorder, and generalized anxiety disorder.

BiotechDigital HealthMental HealthMorristown, US

Sahil V. Kirpekar(President and CEO)inGregory Mayes(Executive Officer, Director)Ellen Lubman(Director)Mark Pollack(Executive Officer)inNathan Bryson(Executive Officer)in Mark Theeuwes(Executive Officer)in

Co-investorsFemHealth Ventures Mitsui Global Investment MPM BioImpact

Rondo Therapeuticsrondotx.com inMar 2022 · $67M

Rondo Therapeutics is an immuno-oncology biopharmaceutical company developing bispecific/multispecific antibody therapeutics designed for tumor-selective targeting to treat solid tumors while sparing healthy tissue.

BiotechHealthtech

Shelley Force Aldred(Co-Founder & Chief Executive Officer)in Nathan Trinklein(Co-Founder, President & CSO)inKatherine(Chief Development Officer)Thomas(Chief Medical Officer)

Co-investorsCanaan Partners Red Tree Venture SV Health Investors Johnson & Johnson Innovation – JJDC

Sidera Biosiderabio.com

Sidera Bio is a biotechnology company using human genetics to develop new medicines for patients.

Biotech

Co-investorsCatalio Capital Management, LP RA Capital Forbion

Sparrow Quantumsparrowquantum.com in 𝕏Apr 2025

Sparrow Quantum develops quantum computing technology, building on research from the Niels Bohr Institute in Copenhagen where the company originated.

Deep TechHardwareQuantum ComputingCopenhagen, DK

Co-investorsLIFTT Scale Capital 2xN Balderton Capital European Investment Bank

Subrasubra.dk inApr 2026

Subra develops scalable superconductor solutions aimed at improving energy transmission and infrastructure.

CleantechDeep TechEnergy

Co-investorsEnBW New Ventures GmbH

Supira Medicalsupiramedical.com inMar 2025 · $120M

Supira Medical develops a next-generation percutaneous ventricular assist device (pVAD) to provide temporary mechanical circulatory support for high-risk patients undergoing coronary interventions and those in cardiogenic shock.

HardwareHealthtechMedical DevicesCampbell, US

Nitin Salunke(President & CEO)inJean Orth(Executive Officer)Mariam Maghribi(Executive Officer, Director)

BoardCasey Gordon(Director)Christopher Shen(Director)Bihua Chen(Director)

Co-investors415 Capital Amed Ventures The Capital Partnership Unorthodox Ventures

Terremotobioterremotobio.comApr 2026 · $108M

Terremoto Biosciences is a clinical-stage biotech developing precision therapies for oncology and genetic diseases using lysine-targeted covalent chemistry.

BiotechDeep TechSouth San Francisco, US

Grace Lu(Executive Officer)James Christensen(Executive Officer, Director)Charles Baum(Executive Officer, Director)in

BoardMichael Goller(Director)Reid Huber(Director)in Peter Thompson(Director)in

Co-investorsEcoR1 Capital OrbiMed RA Capital Osage University Partners Third Rock Ventures

The Protein Brewerytheproteinbrewery.nl inSep 2025 · $35.6M

The Protein Brewery develops FERMOTEIN, a fermentation-based whole food ingredient made from fungal mycelium that provides complete protein and prebiotic fiber.

BiotechFoodTechBreda, NL

Thijs Bosch(CEO)in

Co-investorsUnovis Asset Management Invest-NL

Tribune Therapeutics ABtribunetx.com inMar 2025

Tribune Therapeutics is a preclinical biopharmaceutical company developing medicines that target CCN protein family signaling (such as CCN2/CTGF) to block fibrotic pathways.

BiotechHealthtech

Ole Kaasbøll(Co-founder)

Co-investorsHealthCap Industrifonden Innovestor Ventures LifeArc Ventures Investinor

Wcgclinicalwcgclinical.com in 𝕏

WCG advances clinical trial efficiency and outcomes through research services and advisory support.

AI & Machine LearningBiotechDigital HealthEnterprise SoftwareHealthtechMedical DevicesSaaS

Co-investorsLeonard Green

Windward Biowindwardbio.com in

Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological conditions such as asthma, COPD, and dermatological diseases.

BiotechHealthtech

Co-investorsOrbiMed Quan Capital RA Capital Sanofi Ventures SR One Capital Management Janus Henderson Investors +3 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

AgnextAquafortusAristea TherapeuticsAvalynBGVCheckmate Pharmaceuticals Glycomine ManaT Bio Ray Therapeutics SiteOne Therapeutics Stargazer Pharmaceuticals Weight

Exits · 19

15 IPOs · 4 acquisitions

AnaptysBioNASDAQ: ANABAvalyn Pharma IncNASDAQ: AVLNBolt BiotherapeuticsNASDAQ: BOLTDamora TherapeuticsNASDAQ: DMRADisc MedicineNASDAQ: IRONEdgewise TherapeuticsNASDAQ: EWTXHarmony BiosciencesNASDAQ: HRMYHemab TherapeuticsNASDAQ: COAGMapLight TherapeuticsNASDAQ: MPLTMirum PharmaceuticalsNASDAQ: MIRMNkarta, Inc.NASDAQ: NKTXOnkure Therapeutics IncNASDAQ: OKURPraxisNASDAQ: PRAXRecursion (NASDAQ: RXRX)NASDAQ: RXRXSpruce BiosciencesNASDAQ: SPRBBluejay Therapeuticsacq. by Mirum PharmaceuticalsCheckmate Pharmaceuticalsacq. by Regeneron PharmaceuticalsLimmaTech Biologicsacq. by LillySiteOne Therapeuticsacq. by Eli Lilly and Company

Portfolio news

latest coverage across their companies

Damora Therapeutics: Potential Payday Is A Long Way Off (NASDAQ:DMRA) | Seeking Alpha

Damora Therapeutics · seekingalpha.com · Sep 15, 2026

Novonesis stock gains attention as Maharashtra enzyme investment and recent results shape outlook

Novonesis · ad-hoc-news.de · Sep 6, 2026

Atira Raises $15 Mn to Bring AI Automation to Industrial Sales

Commit Biologics · startuprise.co.uk · Sep 4, 2026

National Hummingbird Day - September 5

Hummingbird · daysofobservance.com · Sep 4, 2026

AnaptysBio earnings on deck: Can Jemperli offset revenue slide? By Investing.com

AnaptysBio · investing.com · Aug 30, 2026

Analyzing Inventiva (NASDAQ:IVA) and Kiora Pharmaceuticals (NASDAQ:KPRX) - Markets Daily

Inventiva · themarketsdaily.com · Aug 26, 2026

Sparrow Quantum Selected for EuroHPC Quantum Grand Challenge Funding - HPCwire

Sparrow Quantum · hpcwire.com · Aug 26, 2026

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

Disc Medicine · prnewswire.com · Aug 18, 2026

IPO stake values · per SEC filings · 12

Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.

Company	Owned	IPO price	At IPO	Stake value
AnaptysBio	8.3%	$68.50	Oct 2017	$132.7M
Harmony Biosciences	6.7%	$24.00	Aug 2020	$102.7M
Bolt Biotherapeutics	13.0%	$20.00	Feb 2021	$90.1M
Edgewise Therapeutics	10.4%	$16.00	Mar 2021	$79.4M
Hemab Therapeutics	9.5%	$18.00	May 2026	$75.2M
Spruce Biosciences	21.3%	$15.00	Oct 2020	$71.1M
Avalyn Pharma Inc	8.0%	$18.00	Apr 2026	$59.9M
Mirum Pharmaceuticals	9.6%	$20.00	Jan 2020	$48.9M
MapLight Therapeutics	7.1%	$17.00	Oct 2025	$46.5M
Onkure Therapeutics Inc	11.4%	$15.00	Apr 2021	$41.5M
Damora Therapeutics	8.8%	$15.00	Oct 2020	$32.5M
Praxis	3.3%	$18.25	May 2021	$26.3M

Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).

Frequently asked questions

How many investments has Novo Holdings made?: Novo Holdings has 120 tracked investments, 19 of which have exited, including 22 dated in the last 24 months.
What stage does Novo Holdings invest at?: Novo Holdings invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What is Novo Holdings's typical check size?: Novo Holdings typically writes checks of $1.1M – $54M.
What sectors does Novo Holdings focus on?: Novo Holdings focuses on AgTech, Biotech, Cleantech, Climate Tech, Digital Health, Healthtech, Impact & Social Good, Longevity, Medical Devices, New Materials.
Where is Novo Holdings located?: Novo Holdings is headquartered in Copenhagen, DK.
Does Novo Holdings lead rounds?: Novo Holdings has led 18 of the 49 rounds where its role is on record.
Who does Novo Holdings co-invest with?: Novo Holdings most often shares deals with Jeito Capital, Industrifonden, OrbiMed, among 47 tracked co-investors.

Images

Co-investors · 10

Canaan Partners

Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.

Both backed · 4

Acesion Pharma ApS Genome Rondo Therapeutics Stargazer Pharmaceuticals

$500K – $20M

Abingworth

Abingworth is a life science venture capital firm that backs early-stage biopharma and biotech companies, helping entrepreneurs translate scientific discoveries into new therapeutics.

Both backed · 4

Onkure Therapeutics Inc Spruce Biosciences Glycomine Myricx Bio

$15M – $30M

Roche Venture Fund

Roche Venture Fund is a corporate venture arm that invests in early-stage biotech and diagnostics companies across more than 10 countries, with a portfolio exceeding 30 portfolio companies. The fund is headquartered in Basel, Switzerland.

Both backed · 2

GlycoEra NMD Pharma

$648K – $3.2M

MPM BioImpact

MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.

Both backed · 1

Reunion Neuroscience

$1M – $15M

Apollo Health Ventures

Apollo Health Ventures is a biotech-focused investor that combines traditional funding with venture building to back transformative healthcare and longevity companies in Europe and the US.

Both backed · 1

Boostertx

Bain Capital Life Sciences

Bain Capital Life Sciences, founded in 2016, invests in biopharmaceutical, medical device, diagnostic, and life science tool companies globally, focusing on companies addressing unmet medical needs and driving medical innovation.

Both backed · 1

Disc Medicine

Uncork Capital

Uncork Capital (formerly SoftTech VC) is a seed-stage venture firm that invests early in founders, with a focus on AI-native companies building leverage and scale.

$3M – $5M

Xfund

Xfund is a venture capital partnership connecting leading VC firms with top research universities in the US and abroad, backing entrepreneurs with multidisciplinary backgrounds building technology companies.

$50K – $500K

JAZZ Venture Partners

JAZZ Venture Partners is a venture capital firm investing in companies at the intersection of technology, neuroscience, and human performance, spanning digital health, biosciences, and AI.

$100K – $20M

6 Dimensions Capital

6 Dimensions Capital is a healthcare-focused investment firm with offices in Boston, San Francisco, Hong Kong, and Shanghai. It backs healthcare startups and growth-stage companies operating in the U.S., Europe, China, Israel, and other markets, with an emphasis on life sciences businesses spanning China and the United States.

Firms observed investing alongside Novo Holdings, from public investor directories. Shared companies are the overlap with Novo Holdings's recorded portfolio.

Similar investors

Sofinnova Partners

Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.

$540K – $27M

Khosla Ventures

Khosla Ventures is a venture capital firm founded by Vinod Khosla.

$5K – $50M

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M

Better Ventures Central Llc

Better Ventures is an early-stage venture capital firm backing mission-driven technology companies working to build a better world across climate, health, and workforce sectors.

$500K – $1.5M

BDC Fund Investments (Fund-of-Funds)

BDC Fund Investments is the fund-of-funds arm of BDC Capital that acts as a limited partner in venture and growth capital funds backing technology-focused Canadian companies. It supports emerging and established fund managers to strengthen Canada's innovation ecosystem.

Featured in lists

Investors & VC Firms in North America Investors & VC Firms in United States Seed Investors & VC Firms Series A Investors & VC Firms Pre-Seed Investors & VC Firms Seed Investors & VC Firms in North America Investors & VC Firms in Europe Seed Investors & VC Firms in United States Growth Investors & VC Firms Series A Investors & VC Firms in North America Series B Investors & VC Firms Series A Investors & VC Firms in United States